Semaglutide News

India's Zydus, Lupin sign deal to co‑market Semaglutide injections - Reuters

India's Zydus, Lupin sign deal to co‑market Semaglutide injections Reuters

When generic versions of weight-loss drugs arrive, public plans should cover them, experts say - The Globe and Mail

When generic versions of weight-loss drugs arrive, public plans should cover them, experts say The Globe and Mail

Sudden Sight Loss Risk Almost 5x Higher With Wegovy Than Ozempic, Study Finds - ScienceAlert

Sudden Sight Loss Risk Almost 5x Higher With Wegovy Than Ozempic, Study Finds ScienceAlert

Semaglutide is going off-patent in India. But will people who need it be able to get it? - statnews.com

Semaglutide is going off-patent in India. But will people who need it be able to get it? statnews.com

India's Zydus, Lupin sign deal to co‑market Semaglutide injections - Yahoo Finance

India's Zydus, Lupin sign deal to co‑market Semaglutide injections Yahoo Finance

Eccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of Obesity - BioSpace

Eccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of Obesity BioSpace

Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom - NDTV

Cheap Generic Ozempic To Hit India: Patent Exit Sparks Weight-Loss Drug Boom NDTV

Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India - lupin.com

Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India lupin.com

Cleveland Clinic study reveals what happens when patients stop taking GLP-1 drugs - The Brighter Side of News

Cleveland Clinic study reveals what happens when patients stop taking GLP-1 drugs The Brighter Side of News

More Options, More Support: New Compounded Semaglutide Pill from Hims & Hers - Hims

More Options, More Support: New Compounded Semaglutide Pill from Hims & Hers Hims

Semaglutide Shows Comparable Glycemic Control Compared With Dulaglutide - Drug Topics

Semaglutide Shows Comparable Glycemic Control Compared With Dulaglutide Drug Topics

Semaglutide Linked to Lower Thyroid Eye Disease Risk in Type 2 Diabetes Mellitus - Optometry Advisor

Semaglutide Linked to Lower Thyroid Eye Disease Risk in Type 2 Diabetes Mellitus Optometry Advisor

India’s Zydus, Lupin sign deal to co‑market Semaglutide injections - WKZO

India’s Zydus, Lupin sign deal to co‑market Semaglutide injections WKZO

FDA issues warning to Novo Nordisk on unreported semaglutide safety events - Pharmaceutical Technology

FDA issues warning to Novo Nordisk on unreported semaglutide safety events Pharmaceutical Technology

Indian Semaglutide Generics Test Novo Nordisk’s Pricing Power And Growth Story - simplywall.st

Indian Semaglutide Generics Test Novo Nordisk’s Pricing Power And Growth Story simplywall.st

What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights - Cleveland Clinic Newsroom

What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights Cleveland Clinic Newsroom

What Are Semaglutide Generics? Here's Why They Matter More In India Now - NDTV

What Are Semaglutide Generics? Here's Why They Matter More In India Now NDTV

Obesity Medications Get New Guidance - Conexiant

Obesity Medications Get New Guidance Conexiant

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial - Nature

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial Nature

Hims & Hers class action alleges semaglutide GLP-1 products falsely advertised - Class Action Lawsuits

Hims & Hers class action alleges semaglutide GLP-1 products falsely advertised Class Action Lawsuits

Oral Semaglutide Pills for Weight Management: What to Know - Cedars-Sinai

Oral Semaglutide Pills for Weight Management: What to Know Cedars-Sinai

FDA warns consumers not to use counterfeit Ozempic (semaglutide) found - fda.gov

FDA warns consumers not to use counterfeit Ozempic (semaglutide) found fda.gov

Zydus and Lupin sign licensing agreement for co-marketing Semaglutide injection in India - BioSpectrum India

Zydus and Lupin sign licensing agreement for co-marketing Semaglutide injection in India BioSpectrum India

Study Looks at Associations Between Semaglutide and Ischemic Optic Neuropathy - Optometry Advisor

Study Looks at Associations Between Semaglutide and Ischemic Optic Neuropathy Optometry Advisor

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison | International Journal of Obesity - Nature

Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison | International Journal of Obesity Nature

50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026 - NDTV

50+ Branded Semaglutide Generics To Enter India As Diabetes Drug Patent Expires In March 2026 NDTV

The ‘astounding’ rise of semaglutide — and what’s next for weight-loss drugs - Nature

The ‘astounding’ rise of semaglutide — and what’s next for weight-loss drugs Nature

Samsung Bioepis and Epis NexLab to develop long-acting semaglutide - The Pharmaletter

Samsung Bioepis and Epis NexLab to develop long-acting semaglutide The Pharmaletter

Ozempic-Like Drugs Can Help You Lose Weight, But There's a Catch - ScienceAlert

Ozempic-Like Drugs Can Help You Lose Weight, But There's a Catch ScienceAlert

Weight Loss: Semaglutide May Help Treat Osteoarthritis, Study Finds - Healthline

Weight Loss: Semaglutide May Help Treat Osteoarthritis, Study Finds Healthline

Samsung Bioepis, Epis NexLab Partner with G2GBIO to Develop Novel Semaglutide Assets - Contract Pharma

Samsung Bioepis, Epis NexLab Partner with G2GBIO to Develop Novel Semaglutide Assets Contract Pharma

Semaglutide Improves Knee Replacements for Patients with Diabetes - Yale School of Medicine

Semaglutide Improves Knee Replacements for Patients with Diabetes Yale School of Medicine

The Race to Beat Ozempic Is Getting Weird - Men's Health

The Race to Beat Ozempic Is Getting Weird Men's Health

Eccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of Obesity - Business Wire

Eccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of Obesity Business Wire